PF-AtlasКлинические испытания › NCT03956589

Functional Respiratory Imaging and Orkambi in CF

Orkambi · Фаза 4

ID реестра
NCT03956589
Фаза
Фаза 4
Статус
Прекращено
Препарат / вмешательство
Orkambi
Спонсор
University Hospital, Antwerp
Начало
2018-10-01
Набор участников
12
Центры
1

Об исследовании

Open-label study to investigate the effects of Orkambi in CF patients homozygous for the F508del mutation by functional respiratory imaging. Primary endpoints in this study are the changes in Specific airway volumes (siVaw) and Specific Airway resistance (siRaw). A total of 20 ORKAMBI-naive patients with Cystic Fibrosis, homozygous for the F508del mutation will be included in this open label study and will be followed through 3 months of treatment. The treatment will be started after all assessments are performed at visit 1. After the start of the treatment some baseline measurements will be repeated throughout the 3-month treatment period. The patient will be asked to visit the hospital monthly. All study visits should be scheduled around the same time.

Открыть NCT03956589 на ClinicalTrials.gov →

Связанные материалы

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT03956589 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.